z-logo
open-access-imgOpen Access
Rif1 and Exo1 regulate the genomic instability following telomere losses
Author(s) -
Xue Yuan,
Marvin Marcus E.,
Ivanova Iglika G.,
Lydall David,
Louis Edward J.,
Maringele Laura
Publication year - 2016
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/acel.12466
Subject(s) - telomere , telomerase , genome instability , biology , telomere binding protein , dna repair , microbiology and biotechnology , dna damage , genetics , g2 m dna damage checkpoint , cell cycle , cancer research , cell cycle checkpoint , cancer , dna , gene , dna binding protein , transcription factor
Summary Telomere attrition is linked to cancer, diabetes, cardiovascular disease and aging. This is because telomere losses trigger further genomic modifications, culminating with loss of cell function and malignant transformation. However, factors regulating the transition from cells with short telomeres, to cells with profoundly altered genomes, are little understood. Here, we use budding yeast engineered to lack telomerase and other forms of telomere maintenance, to screen for such factors. We show that initially, different DNA damage checkpoint proteins act together with Exo1 and Mre11 nucleases, to inhibit proliferation of cells undergoing telomere attrition. However, this situation changes when survivors lacking telomeres emerge. Intriguingly, checkpoint pathways become tolerant to loss of telomeres in survivors, yet still alert to new DNA damage. We show that Rif1 is responsible for the checkpoint tolerance and proliferation of these survivors, and that is also important for proliferation of cells with a broken chromosome. In contrast, Exo1 drives extensive genomic modifications in survivors. Thus, the conserved proteins Rif1 and Exo1 are critical for survival and evolution of cells with lost telomeres.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here